COGT
Cogent Biosciences, Inc.
$39.38
-1.13
(-2.79%)
Mkt Cap
6.92B
Volume
55,016
52W Range
10.38-43.73
Sector
Healthcare
Beta
0.34
EPS (TTM)
-3.08
P/E Ratio
-13.93
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 7.87M | 22.50M | 9.73M | 8.36M | 6.36M | 2.99M |
| Net Income | (328.94M) | (255.86M) | (192.41M) | (140.24M) | (72.27M) | (74.81M) | (30.27M) | (34.53M) | (25.49M) | (18.12M) | (6.59M) |
| EPS | -2.55 | -2.46 | -2.42 | -2.26 | -1.85 | -6.00 | -3.97 | -5.55 | -3.45 | -3.10 | -1.13 |
| Free Cash Flow | (266.00M) | (208.36M) | (156.42M) | (125.50M) | (60.48M) | (35.85M) | (41.55M) | (33.04M) | (26.75M) | (21.95M) | 15.72M |
| FCF / Share | -3.93 | -2.01 | -1.96 | -2.14 | -1.56 | -3.24 | -5.45 | -5.31 | -3.62 | -3.75 | 2.69 |
| Operating CF | (264.44M) | (207.79M) | (153.62M) | (118.64M) | (58.76M) | (35.85M) | (41.51M) | (32.49M) | (25.84M) | (18.64M) | 17.72M |
| Total Assets | 937.61M | 327.90M | 313.44M | 300.81M | 232.09M | 250.92M | 49.42M | 85.93M | 49.12M | 75.55M | 94.77M |
| Total Debt | 253.15M | 17.47M | 18.85M | 19.65M | 3.15M | 5.21M | 6.03M | 0 | 0 | 0 | 0 |
| Cash & Equiv | 312.01M | 98.17M | 53.23M | 139.89M | 219.68M | 242.19M | 37.42M | 55.67M | 28.27M | 41.32M | 90.48M |
| Book Value | 636.37M | 256.29M | 257.80M | 255.74M | 214.18M | 234.67M | 31.76M | 60.23M | 28.30M | 52.39M | 69.52M |
| Return on Equity | -0.52 | -1.00 | -0.75 | -0.55 | -0.34 | -0.32 | -0.95 | -0.57 | -0.90 | -0.35 | -0.09 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (97.35M) | (102.49M) | (80.93M) | (73.53M) | (71.99M) | (67.93M) | (70.63M) | (58.95M) | (58.35M) | (54.37M) | (55.38M) | (44.08M) |
| EPS | -0.60 | -1.13 | -0.71 | -0.64 | -0.52 | -0.61 | -0.64 | -0.59 | -0.62 | -0.63 | -0.64 | -0.59 |
| Free Cash Flow | (87.33M) | (79.92M) | (64.35M) | (54.67M) | (67.06M) | (60.65M) | (52.26M) | (42.85M) | (52.60M) | (44.38M) | (38.09M) | (33.32M) |
| FCF / Share | -1.30 | -1.18 | -0.56 | -0.48 | -0.59 | -0.55 | -0.47 | -0.43 | -0.55 | -0.51 | -0.44 | -0.45 |
| Operating CF | (86.88M) | (79.11M) | (64.29M) | (54.54M) | (66.51M) | (60.58M) | (51.98M) | (42.70M) | (52.53M) | (44.07M) | (37.97M) | (32.07M) |
| Total Assets | 903.01M | 937.61M | 425.93M | 274.82M | 283.80M | 327.90M | 384.02M | 429.94M | 476.11M | 313.44M | 355.45M | 392.37M |
| Total Debt | 238.65M | 253.15M | 60.56M | 60.66M | 17.09M | 17.47M | 17.83M | 18.18M | 18.52M | 18.85M | 19.17M | 19.36M |
| Cash & Equiv | 241.21M | 312.01M | 125.30M | 127.60M | 126.00M | 98.17M | 97.05M | 88.22M | 215.80M | 53.23M | 86.81M | 214.32M |
| Book Value | 607.69M | 636.37M | 302.46M | 155.04M | 219.00M | 256.29M | 314.66M | 373.22M | 422.33M | 257.80M | 302.90M | 348.43M |
| Return on Equity | -0.16 | -0.16 | -0.27 | -0.47 | -0.33 | -0.27 | -0.22 | -0.16 | -0.14 | -0.21 | -0.18 | -0.13 |
COGT News
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage Leverage
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results